MIRADOR360
LIVE

Serial Number

98432118

Owner

Mirador Therapeutics, Inc.

Attorney

Brent D. Sokol

Filing Date

Mar 4, 2024

Add to watchlist:

No watchlists yet
View on USPTO

MIRADOR360 Trademark

Serial Number: 98432118

MIRADOR360 is a trademark filed by Mirador Therapeutics, Inc. on March 4, 2024. The trademark is classified under Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Mirador Therapeutics, Inc. (8 trademarks)

3115 Merryfield Row, Suite 210
San Diego, CA 92121

Entity Type: 03

Trademark Details

Filing Date

March 4, 2024

Registration Date

Not Registered

Published for Opposition

February 25, 2025

Goods & Services

Scientific research services in the nature of collecting and analyzing patient data and genetic information for pharmaceutical drug development and diagnostics development including companion diagnostics development and complementary diagnostics development; Scientific research services in the nature of collecting and analyzing patient data including genetic information for selecting and validating therapeutic targets for pharmaceutical development as well as for predicting, measuring or evaluating the performance of therapeutic molecules directed at therapeutic targets; Scientific research services in the nature of collecting and analyzing patient data including genetic information for selecting and validating biomarkers and other criteria for diagnostics including companion diagnostics development and complementary diagnostics development as well as for predicting, measuring or evaluating the performance of the diagnostics; Scientific research services in the nature of collecting and analyzing patient data including genetic information for selecting and validating biomarkers and other criteria for selecting patients for inclusion in clinical treatment including clinical trials as well as for predicting, measuring or evaluating the performance of the patient selecting criteria; Scientific research services in the nature of collecting patient data and genetic information and analysis of such data for identifying and recruiting patients for participation in clinical trials for pharmaceutical drug development, matching patients with clinical trials and for measuring and monitoring the performance of clinical trials for pharmaceutical drug development; providing a platform as a service featuring a computer software platform for selecting, validating and evaluating therapeutic targets and therapeutic molecules in the field of pharmaceutical development; providing a platform as a service featuring a computer software platform for selecting, validating and evaluating biomarkers and other patient-selecting or patient-identifying criteria in the field of diagnostic development including companion diagnostics development and complementary diagnostics development

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 17, 2026 EXRA
SOU EXTENSION 2 GRANTED
Apr 16, 2026 EX2G
SOU EXTENSION 2 FILED
Apr 16, 2026 EXT2
SOU TEAS EXTENSION RECEIVED
Apr 16, 2026 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 2, 2026 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Apr 2, 2026 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Apr 2, 2026 COAR
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 25, 2025 EXRA
SOU EXTENSION 1 GRANTED
Sep 24, 2025 EX1G
SOU EXTENSION 1 FILED
Sep 24, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Sep 24, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Apr 22, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 25, 2025 NPUB
PUBLISHED FOR OPPOSITION
Feb 25, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 19, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 3, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 9, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 9, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 9, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 10, 2024 GNRN
NON-FINAL ACTION E-MAILED
Oct 10, 2024 GNRT
NON-FINAL ACTION WRITTEN
Oct 10, 2024 CNRT
ASSIGNED TO EXAMINER
Sep 18, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 15, 2024 NWOS
NEW APPLICATION ENTERED
Mar 4, 2024 NWAP